Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of PT01 (Pegtomarginase) in Advanced Malignancies
NCT04136834Phase 1Unknown
- Sponsor
- Athenex
- Start
- Apr 2021
- Primary completion
- Dec 2022
- Modality
- Polymer-based Nanoparticles, Replacement Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pegtomarginase in malignant solid tumor and Malignant Melanoma (MM), sponsored by Athenex. Primary endpoints: Maximum Tolerated Dose (MTD) / Recommended Phase 2 Dose (RP2D) at 4 weeks and Treatment-Related Adverse Events. Status: unknown.
02
Drugs
pegtomarginase
03
Conditions
malignant solid tumorMalignant Melanoma (MM)
Beyond the preview
Go deeper on NCT04136834.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04136834.